Lida Bubuteishvili‐Pacaud

1.0k total citations
21 papers, 357 citations indexed

About

Lida Bubuteishvili‐Pacaud is a scholar working on Oncology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lida Bubuteishvili‐Pacaud has authored 21 papers receiving a total of 357 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 9 papers in Epidemiology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lida Bubuteishvili‐Pacaud's work include Neuroendocrine Tumor Research Advances (9 papers), CAR-T cell therapy research (8 papers) and Lung Cancer Research Studies (8 papers). Lida Bubuteishvili‐Pacaud is often cited by papers focused on Neuroendocrine Tumor Research Advances (9 papers), CAR-T cell therapy research (8 papers) and Lung Cancer Research Studies (8 papers). Lida Bubuteishvili‐Pacaud collaborates with scholars based in United States, Germany and Switzerland. Lida Bubuteishvili‐Pacaud's co-authors include Nicola Fazio, Marianne Pavel, Matthew H. Kulke, Maurizio Voi, Juan W. Valle, Eric Van Cutsem, James C. Yao, Edward M. Wolin, Roberto Buzzoni and Jiří Tomášek and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Lida Bubuteishvili‐Pacaud

21 papers receiving 351 citations

Peers

Lida Bubuteishvili‐Pacaud
Comparison fields: 5 of 37
  • Oncology 316
  • Epidemiology 189
  • Neurology 147
  • Molecular Biology 84
  • Hematology 71
Replace Helen L. Lowe with:
Helen L. Lowe United Kingdom
Cameron Dell United States
Satwant Lally United States
W. Victoria Lai United States
Maxim Yankelevich United States
Christopher J. Forlenza United States
Luka Ozretić Germany
Matthew L. Ulrickson United States
Eleonora Pisa Italy
S. Schuster United States
Helen L. Lowe United Kingdom View profile →
Citations per field, relative to Lida Bubuteishvili‐Pacaud
Lida Bubuteishvili‐Pacaud · 1×
Citations per year, relative to Lida Bubuteishvili‐Pacaud
Lida Bubuteishvili‐Pacaud · 1×

Countries citing papers authored by Lida Bubuteishvili‐Pacaud

Since Specialization
Citations

This map shows the geographic impact of Lida Bubuteishvili‐Pacaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lida Bubuteishvili‐Pacaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lida Bubuteishvili‐Pacaud more than expected).

Fields of papers citing papers by Lida Bubuteishvili‐Pacaud

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lida Bubuteishvili‐Pacaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lida Bubuteishvili‐Pacaud. The network helps show where Lida Bubuteishvili‐Pacaud may publish in the future.

Co-authorship network of co-authors of Lida Bubuteishvili‐Pacaud

This figure shows the co-authorship network connecting the top 25 collaborators of Lida Bubuteishvili‐Pacaud. A scholar is included among the top collaborators of Lida Bubuteishvili‐Pacaud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lida Bubuteishvili‐Pacaud. Lida Bubuteishvili‐Pacaud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
2023 ·Journal of Clinical Oncology ·Yi Lin, Thomas Martin, Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, Abhinav Deol, Myo Htut, Alexander M. Lesokhin, Nikhil C. Munshi, Elizabeth O’Donnell, Carolyn C. Jackson, Tzu‐Min Yeh, Arnob Banerjee, Enrique Zudaire, Deepu Madduri, (unknown), Lida Bubuteishvili‐Pacaud, Sundar Jagannath
71
2
A phase 1, open-label, dose escalation and expansion, multicenter study of claudin 18.2-targeted chimeric antigen receptor T-cells in patients with unresectable, locally advanced, or metastatic gastric, gastroesophageal junction, esophageal, or pancreatic adenocarcinoma.
2023 ·Journal of Clinical Oncology ·David B. Zhen, Ramya Thota, (unknown), Dong Geng, Tairan Yang, Chuan Wang, (unknown), Muhammad Akram, (unknown), Lida Bubuteishvili‐Pacaud, Michael K. Gibson
5
3
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.
2023 ·Journal of Clinical Oncology ·Binod Dhakal, Kwee Yong, Simon J. Harrison, María‐Victoria Mateos, Philippe Moreau, Niels W.C.J. van de Donk, Surbhi Sidana, Rakesh Popat, Nikoletta Lendvai, Carolina Lonardi, Ana Slaughter, Jordan M. Schecter, Katherine Li, Enrique Zudaire, Ying Chen, (unknown), Lida Bubuteishvili‐Pacaud, Nitin Patel, Jesús F. San Miguel, Hermann Einsele
20
4
Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.
2022 ·Journal of Clinical Oncology ·Saad Z. Usmani, Thomas Martin, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, Abhinav Deol, Myo Htut, Alexander M. Lesokhin, Nikhil C. Munshi, Elizabeth O’Donnell, Carolyn C. Jackson, Tzu‐Min Yeh, Arnob Banerjee, Enrique Zudaire, Deepu Madduri, Changwei Zhou, Lida Bubuteishvili‐Pacaud, Yi Lin, Sundar Jagannath
10
5
Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A.
2022 ·Journal of Clinical Oncology ·Hermann Einsele, Adam D. Cohen, Michel Delforge, Jens Hillengaß, Hartmut Goldschmidt, Katja Weisel, Marc‐Steffen Raab, Christof Scheid, Jordan M. Schecter, Kevin C. De Braganca, Helen Varsos, Tzu‐Min Yeh, Pankaj Mistry, Tito Roccia, (unknown), Muhammad Akram, Lida Bubuteishvili‐Pacaud, Tonia Nesheiwat, Mounzer Agha, Yaël C. Cohen
5
6
Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric/young adult (YA) patients (Pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).
2020 ·Journal of Clinical Oncology ·Véronique Minard‐Colin, Shannon L. Maude, Jochen Buechner, Joerg Krueger, Franco Locatelli, Andishe Attarbaschi, Theodore W. Laetsch, (unknown), Cristina Díaz de Heredia, Rakesh Awasthi, Simon Newsome, (unknown), Lida Bubuteishvili‐Pacaud, Birgit Burkhardt
6
7
ELARA: A phase II, single-arm, multicenter, open-label trial investigating the efficacy and safety of tisagenlecleucel in adult patients with refractory/relapsed follicular lymphoma (r/r FL).
2019 ·Journal of Clinical Oncology ·Michael Dickinson, Leslie Popplewell, Arne Kolstad, Joy Ho, Takanori Teshima, Martin Dreyling, Stephen J. Schuster, Catherine Thiéblemont, (unknown), (unknown), Tomasz Lawniczek, Lida Bubuteishvili‐Pacaud, Nathan Fowler
5
8
Considerations for tisagenlecleucel dosing rationale.
2018 ·Journal of Clinical Oncology ·Rakesh Awasthi, Karen Thudium Mueller, Gregory A. Yanik, Constantine S. Tam, Susana Rives, Joseph P. McGuirk, Michael W. Boyer, Ulrich Jäger, André Baruchel, Gary Douglas Myers, Peter Borchmann, Samantha Jaglowski, Heather E. Stefanski, Michael Bishop, Edward Waldron, Jason S. Hamilton, (unknown), Lida Bubuteishvili‐Pacaud, Edmund K. Waller
5
9
Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.
2018 ·Journal of Clinical Oncology ·Karen Thudium Mueller, Stephan A. Grupp, Shannon L. Maude, John E. Levine, Michael A. Pulsipher, Michael W. Boyer, Keith J. August, Gary Douglas Myers, Rakesh Awasthi, Edward Waldron, Lida Bubuteishvili‐Pacaud, Tanya Taran, (unknown), Constantine S. Tam, Ulrich Jäger, Ronan Foley, Peter Borchmann, Stephen J. Schuster, Edmund K. Waller, Theodore W. Laetsch
3
10
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
2017 ·Annals of Oncology ·Matthew H. Kulke, Philippe Ruszniewski, Eric Van Cutsem, Catherine Lombard‐Bohas, Juan W. Valle, Wouter W. de Herder, Marianne Pavel, Evgeny Degtyarev, Jan C. Brase, Lida Bubuteishvili‐Pacaud, Maurizio Voi, Ramón Salazar, Ivan Borbath, Nicola Fazio, Denis Smith, Jaume Capdevila, Rachel P. Riechelmann, Jin‐Guang Yao
82
11
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary
2017 ·Neuroendocrinology ·Simron Singh, Carlo Carnaghi, Roberto Buzzoni, Rodney F. Pommier, Markus Raderer, Jiří Tomášek, Harald Lahner, Juan W. Valle, Maurizio Voi, Lida Bubuteishvili‐Pacaud, Jeremie Lincy, Edward M. Wolin, Natsuko Okita, Steven K. Libutti, Do‐Youn Oh, Matthew H. Kulke, Jonathan Strosberg, James C. Yao, Marianne Pavel, Nicola Fazio, (unknown)
38
12
Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis
2017 ·Cancer Science ·Nicola Fazio, Roberto Buzzoni, Gianfranco Delle Fave, Margot Tesselaar, Edward M. Wolin, Eric Van Cutsem, Paola Tomassetti, Jonathan Strosberg, Maurizio Voi, Lida Bubuteishvili‐Pacaud, Antonia Ridolfi, (unknown), Jiří Tomášek, Simron Singh, Marianne Pavel, Matthew H. Kulke, Juan W. Valle, James C. Yao
62
13
Health-related quality of life (HRQoL) in patients with advanced neuroendocrine tumors (NET) of gastrointestinal origin in the phase 3 RADIANT-4 trial.
2017 ·Journal of Clinical Oncology ·Simron Singh, Jonathan Strosberg, Lida Bubuteishvili‐Pacaud, Evgeny Degtyarev, Maureen P. Neary, Matthias Hünger, Jennifer Eriksson, (unknown), Nicola Fazio, Matthew H. Kulke, Marianne Pavel, James C. Yao
1
14
Impact of prior therapies on everolimus treatment in the subgroup of patients with advanced lung neuroendocrine tumors (NET) in the RADIANT-4 trial
2016 ·Annals of Oncology ·Roberto Buzzoni, Gianfranco Delle Fave, Jonathan Strosberg, Maurizio Voi, Antonia Ridolfi, Lida Bubuteishvili‐Pacaud, (unknown), Edward M. Wolin, Nicola Fazio
1
15
Association of disease progression, health-related quality of life (HRQoL), and utility in patients (pts) with advanced, nonfunctional, well-differentiated gastrointestinal (GI) or lung neuroendocrine tumors (NET) in the phase 3 RADIANT-4 trial.
2016 ·Journal of Clinical Oncology ·Simron Singh, Marianne E. Pavel, Jonathan Strosberg, Lida Bubuteishvili‐Pacaud, Evgeny Degtyarev, Maureen P. Neary, Matthias Hünger, Jennifer Eriksson, Nicola Fazio, Matthew H. Kulke, James C. Yao
2
16
Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: Second interim overall survival (OS) results from the RADIANT-4 study.
2016 ·Journal of Clinical Oncology ·James C. Yao, Nicola Fazio, Simron Singh, Roberto Buzzoni, Carlo Carnaghi, Edward M. Wolin, Jiří Tomášek, Markus Raderer, Harald Lahner, Maurizio Voi, Lida Bubuteishvili‐Pacaud, Jeremie Lincy, Juan W. Valle, Gianfranco Delle Fave, Eric Van Cutsem, Do‐Youn Oh, Jonathan Strosberg, Matthew H. Kulke, Marianne Pavel, (unknown)
6
17
Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial.
2016 ·Journal of Clinical Oncology ·Simron Singh, Carlo Carnaghi, Roberto Buzzoni, Rodney F. Pommier, Markus Raderer, Jiří Tomášek, Harald Lahner, Juan W. Valle, Maurizio Voi, Lida Bubuteishvili‐Pacaud, Jeremie Lincy, Carolin Sachs, Natsuko Okita, Steven K. Libutti, Do‐Youn Oh, Matthew H. Kulke, Jonathan Strosberg, James C. Yao, Marianne Pavel, Nicola Fazio, (unknown)
6
18
Health-related quality of life (HRQoL) in patients with advanced, nonfunctional, well-differentiated gastrointestinal (GI) or lung neuroendocrine tumors (NET) in the phase 3 RADIANT-4 trial.
2016 ·Journal of Clinical Oncology ·Marianne Pavel, Jonathan Strosberg, Lida Bubuteishvili‐Pacaud, Evgeny Degtyarev, Maureen P. Neary, Matthias Hünger, Jennifer Eriksson, Nicola Fazio, Matthew H. Kulke, Simron Singh, James C. Yao
3
19
Abstract S6-5: Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer
2012 ·Cancer Research ·David Cameron, Julia Brown, Rebecca Dent, C Jackisch, John R. Mackey, Xavier Pivot, G. Steger, Thomas Suter, Masakazu Toi, Mahesh Parmar, Lida Bubuteishvili‐Pacaud, Volkmar Henschel, R. Laeufle, (unknown)
9
20
Abstract P3-06-34: Plasma (p) VEGF-A and VEGFR-2 biomarker (BM) results from the BEATRICE phase III trial of bevacizumab (BEV) in triple-negative early breast cancer (BC)
2012 ·Cancer Research ·Peter Carmeliet, Céline Pallaud, (unknown), Lida Bubuteishvili‐Pacaud, Volkmar Henschel, Rebecca Dent, Rachel Bell, John R. Mackey, (unknown), David Cameron
3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Helen L. Lowe Breakdown of academic impact, for papers by Cameron Dell Breakdown of academic impact, for papers by Satwant Lally Breakdown of academic impact, for papers by W. Victoria Lai Breakdown of academic impact, for papers by Maxim Yankelevich Breakdown of academic impact, for papers by Christopher J. Forlenza Breakdown of academic impact, for papers by Luka Ozretić Breakdown of academic impact, for papers by Matthew L. Ulrickson Breakdown of academic impact, for papers by Eleonora Pisa Breakdown of academic impact, for papers by S. Schuster
Rankless by CCL
2026